. Author manuscript; available in PMC: 2012 Dec 15.

Published in final edited form as: Clin Cancer Res. 2011 Oct 28;17(24):7693–7703. doi: 10.1158/1078-0432.CCR-11-1488

Table 1.

¹¹¹In-R1507 tumor uptake and distribution in bone sarcoma xenografts

Xenograft	IGF-1R status	Response to R1507 [Kolb et al. (11)and Supplemental Figure 1]	Tumor ¹¹¹In-R1507 uptake on day 3 p.i.	¹¹¹In-R1507 distribution on immuno-SPECT
OS-1	positive	high	27.5 ± 6.5 %ID/g^,^*	homogeneous
EW-5	positive	intermediate	14.0 ± 2.8 %ID/g^, ^*	heterogeneous
EW-8	positive	low	6.5 ± 1.5 %ID/g^*	non-specific
OS-33	negative	low	5.5 ± 0.6 %ID/g^*	non-specific

R1507 responsive tumors (OS-1 and EW-5) differed significantly from non-responsive tumors (EW-8 and OS-33) concerning ¹¹¹In-R1507 tumor uptake (p<0.05)

^**

R1507 high(OS-1) and intermediate (EW-5) responsive tumors also differed significantly from each other concerning ¹¹¹In-R1507 tumor uptake (p<0.05)